May 15, 2020
Transgene, NEC algorithm looks accurate in spotting cancer mutations
T G4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene’s proprietary myvac® platform with NEC’s cutting-edge…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Transgene
May 6, 2020
Transgene posts €35.3 million in cash and cash equivalents in Q1 2020
Transgene posts €35.3 million in cash and cash equivalents in Q1 2020, with minor impact from the Covid-19 pandemic seen to-date
September 30, 2019
Transgene reports first promising results with TG4001 plus Avelumab in HPV-Positive cancers
Transgene posted promising result at ESMO, of TG4001 plus Bavencio (avelumab) in HPV-16 positive cancers, from a clinical trial conducted…
September 18, 2019
Transgene posts second quarter €15.3M net loss
Transgene has posted net loss amounted to €15.3 million for the first half of 2019 compared to €14.9 million for the same period in 2018, while its cash, cash equivalents and other financial assets amounted to €12.8 million versus €16.9 million as of December 31, 2018.
July 11, 2019
Transgene Receives MHRA Approval for Lead myvac™ Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
Phase 1 clinical trial, expected to start in H2 2019, will be co-funded by Transgene and its collaboration partner NEC…
May 28, 2019
Transgene included last patient in Phase 2 trial testing TG4010 in combination with Opdivo
Transgene confirms that the study’s primary
endpoint (objective response rate – ORR) on a minimum of 35 evaluable
patients will be reported in Q4 2019.
May 13, 2019
Transgene gets FDA IND clearance to start clinical trial of myvac for ovarian cancer treatment
Transgene can start linical trial of its lead myvac™ candidate TG4050as a potential treatment for ovarian cancer patients after first-linesurgery and chemotherapy
May 2, 2019
Transgene, AstraZeneca in exclusive license option deal for new oncolytic immunotherapies
Transgeen in agreement with AstraZeneca to co-developfive armed oncolytic vaccinia virus candidates. Innovative oncolyticviruses resulting from this collaboration will use Transgene’sproprietary next generation viral platform Invir.IO
March 20, 2019
Transgene: A Positive 2018, Moving Ahead with a Strong Portfolio
2018 Full-year results and business update Clinical trials set to announce key data in 2019 Invir.IO™ platform designed to deliver…
March 18, 2019
Transgene Secures a €20 Million Revolving Credit Facility with Natixis
STRASBOURG, France–(BUSINESS WIRE)– Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and…